Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

Similar documents
Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease

IBD high risk groups

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

The variable risk of colorectal cancer in patients with inflammatory bowel disease.

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Diagnostic techniques for surveillance of dysplasia

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

Implementation of disease and safety predictors during disease management in UC

Ulcerative colitis (UC) and Crohn s disease (CD) have

Positioning Biologics in Ulcerative Colitis

IBD and Cancer: Myths and Facts

Primary sclerosing cholangitis (PSC) is a chronic, cholestatic

CRC and Dysplasia in IBD: Objectives of Talk. Colorectal Cancer and Dysplasia in IBD: A Case-Based Approach. Page 1

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =

To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,

Mucosal healing: does it really matter?

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Personalized Medicine in IBD: Where Are We in 2013

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Pouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD

Colorectal Cancer in Inflammatory Bowel Disease

Clinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study

Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts

Correspondence should be addressed to Mary Shuhaibar;

Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn s disease

Spectrum of Diverticular Disease. Outline

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Endoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.

Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn s disease

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study

As clinicians we would all agree that the goal for our

Ulcerative Colitis: State of the Art 2006

P rimary sclerosing cholangitis (PSC) is a chronic cholestatic

Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis

C olorectal cancer (CRC) is one of the most feared

5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Genetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease

PEDIATRIC INFLAMMATORY BOWEL DISEASE

Crohn disease is a chronic inflammatory bowel disease

HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER

There is a well-established association between inflammatory

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

Recent Advances in the Management of Refractory IBD

Endpoints for Stopping Treatment in UC

Increased Risk of Primary Sclerosing Cholangitis and Ulcerative Colitis in First-Degree Relatives of Patients With Primary Sclerosing Cholangitis

How to characterize dysplastic lesions in IBD?

Inflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital

The role of Surgery and Stomas in IBD

Patients with longstanding ulcerative colitis (UC) or

Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery

September 12, 2015 Millie D. Long MD, MPH, FACG

Staying Healthy as an IBD patient

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?

Disease behavior in adult patients- are there predictors for stricture or fistula formation?

SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017

Surgery in Inflammatory Bowel Disease. Rajesh Gupta MS, MCh Surgical Gastroenterology Division Dept of General Surgery PGIMER, Chandigarh

Microbiome, Inflammation and Cancer

Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC

Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

Crohn s disease is a chronic idiopathic disease of the

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

AESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients

The pathology of IBD and its modification by liver disease. Roger Feakins ESP/H-ECCO

Risk for Colorectal Neoplasia in Patients With Colonic Crohn s Disease and Concomitant Primary Sclerosing Cholangitis

Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis

Recurrence and survival rates of inflammatory bowel disease-associated colorectal cancer following postoperative chemotherapy: a comparative study

Cancer Risk with IBD Therapies How to Discuss with your Patients?

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Ileoanal Pouch Solves the Problem

POST TRANSPLANT OUTCOMES IN PSC

Objec-ve. Case Presenta-ons and Ques-ons to Panel. Dysplasia case 11/13/11

Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease

Primary sclerosing cholangitis and primary biliary cirrhosis: epidemiology, risk factors, and outcome Boonstra, K.

IBD What s in it for you?

Quality in Endoscopy: Can We Do Better?

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

I nflammatory bowel diseases (IBD) are chronic intestinal

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?

Protocol for the management of acute severe ulcerative colitis in children

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers

Transcription:

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

Endpoints Overview Hospitalization Surgery Colorectal cancer Death Risk Factors Extent Age at Diagnosis PSC

Rochester Epidemiology Project Mayo Clinic and Olmsted Medical Group provide essentially all medical care Computer linkage for medical diagnoses, surgical procedures Access to records of all providers, including ambulatory care Identifies full spectrum of disease Over 1600 epidemiological reports on acute and chronic disease Melton LJ, Mayo Clin Proc 1996;71:266

UC Cohort, Olmsted County, 1970-2004 Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

UC Cohort, Olmsted County, 1970-2004 Ingle SB et al. DDW 2007, UEGW 2007 and ACG 2007 abstracts.

Cumulative Risk Of Hospitalization From UC Diagnosis 28.8% 38.7% 49.8% Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Cumulative Risk Of Hospitalization, Stratified By Decade Of UC Diagnosis 45% 30% 20% Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Cumulative Risk Of Hospitalization, Stratified By Initial UC Extent Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Cumulative Risk Of Hospitalization, Stratified By Initial Need For Corticosteroids Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Cumulative Risk Of Hospitalization, Stratified By Initial Need For Hospitalization Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Risk Of Initial Hospitalization After First 90 Days: Cox proportional hazards regression HR (95% CI) P-value Extensive disease 1.58 (1.10-2.26) 0.0126 Early steroid use 1.85 (1.23-2.80) 2.80) 0.0035 Early hospitalization 1.61 (1.08-2.40) 0.0182 Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

UC Hospitalization - Conclusions 47% of UC patients were hospitalized at least once between 1970 and 2004 Mean length of stay of 9.6 days 5-year cumulative risk of hospitalization increased from 20.2% in the 1970's to 44.7% in 2000-2004. 2004. Extensive disease, early corticosteroid use and early hospitalization were associated with increased risk of hospitalization. Ingle SB et al. DDW 2007, UEGW 2007, and ACG 2007 abstracts.

Surgery in UC - Study Population, 1970-2004 365 UC pts were followed for 5,260 person-years (median follow-up was 13.8 years; range, 1 month -36 years). 23% (85/365) of pts had at least one surgery. 21% (75/365) of pts had a colectomy 71% (60/85) of pts had more than one surgery. Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

Colectomy Type Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

Cumulative Risk Of Colectomy By UC Duration 13.1% 19.4% 27.5% Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

Cumulative Risk Of Colectomy Stratified by Gender HR= 2.26 (1.3-3.8) Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

Cumulative Risk Of Colectomy Stratified By Decade Of Diagnosis HR=3.9 (1.7 8.7) HR=2.3 (1.2-2.6) HR=1.3 (0.6 2.7) HR=1.0 Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

UC Surgery - Conclusions Among 365 UC patients diagnosed between 1970-2004, 20.5% required colectomy. The cumulative incidence of colectomy increased to 19.4% at 10 years and almost 30% at 25 years from UC diagnosis. Male gender and diagnosis after 1990 were associated with greater risk of colectomy. Ingle SB et al. ACG 2007 and UEGW 2007 abstracts.

Risk of Colorectal Cancer in UC Meta-Analysis 25 20 UC Cumulative probability (%) 15 10 5 Control 0 0 5 10 15 20 25 30 Time from diagnosis (years) Eaden: : Gut 2001; 48:526 CP1169260-22

Risk Factors for IBD-Related Colorectal Cancer Classic risk factors Increased extent (i.e., pancolitis vs. proctitis) Increased duration Newer risk factors Primary sclerosing cholangitis (PSC) Family history of CRC Backwash ileitis? Severity of inflammation?

Cumulative Risk of Colorectal Cancer Among 376 Ulcerative Colitis Patients From Olmsted County, 40 Minnesota Cumulative incidence of colorectal cancer (%) 30 20 10 Observed Expected No. at risk 0 0 10 20 30 40 Years from diagnosis 376 220 109 46 10 Jess T, et al, Gastroenterology 2006 CP1188395-2

Colorectal Cancer Risk in UC - Olmsted County, 1940-2001 Patients(n (n) Person-years Obs Exp SMR (95% CI) Total 378 5567 6 5.38 1.1 (0.4-2.4) Gender Women 166 2618 2 2.56 0.8 (0.1-2.8) Men 212 2949 4 2.82 1.4 (0.4-3.6) Age at diagnosis (yrs) 0-29 149 2273 1 0.43 2.3 (0.1-12.8) 30-49 144 2288 4 1.86 2.2 (0.6-5.5) 50+ 85 1006 1 3.09 0.3 (0.01-1.8) Calendar year at diagnosis 1940-1959 1959 34 874 1 1.20 0.8 (0.02-4.6) 1960-1979 1979 143 2933 5 1.92 1.9 (0.6-4.5) 1980-1989 1989 85 1084 0 0.00 0.0 (0.0-3.9) 1990-2002 116 676 0 0.00 0.0 (0.0-7.7) Jess T et al, Gastroenterology 2006

Overall Survival From Diagnosis of 378 Ulcerative Colitis Patients From Olmsted County, Minnesota, 1940-2001 62 deaths total 12 deaths (19%) due to GI causes or GI cancers Jess T et al, Gut 2006

Cause-Specific Mortality in Ulcerative Colitis Women Men Causes Obs Exp SMR(95% CI) Obs Exp SMR(95% CI) Infection 0 0.5 0.0 (0.0-7.4) 0 0.9 0.0 (0.0-4.0) Cancer 5 8.2 0.6 (0.2-1.4) 10 11.0 0.9 (0.4-1.7) Intestinal 1 1.0 1.0 (<0.1-5.3) 4 1.2 3.3 (0.9-8.4) Pulmonary 0 1.6 0.0 (0.0-2.4) 2 3.9 0.5 (0.1-1.9) 1.9) Heme 0 0.1 0.0 (0.0-26) 1 0.1 7.1 (0.2-39) CNS 2 0.7 3.1 (0.4-11) 1 0.7 1.5 (<0.1-8.3) Cardiac 8 18.1 0.4 (0.2-0.9*) 0.9*) 15 18.9 0.8 (0.4-1.3) Respiratory 4 2.9 1.4 (0.4-3.5) 2 3.6 0.6 (0.1-2.0) GI 2 1.3 1.5 (0.2-5.5) 4 1.7 2.4 (0.7-6.2) GU 2 0.7 2.7 (0.3-10) 0 0.6 0.0 (0.0-6.1) Suicide 0 0.2 0.0 (0.0-16) 1 1.0 1.0 (<0.1-5.6) Accidents 1 0.9 1.2 (<0.1-6.5) 1 2.0 0.5 (<0.1-2.8) All other 2 2.2 0.9 (0.1-3.4) 1 2.3 0.4 (0.1-2.4) Total 26 36.3 0.7 (0.5-1.1) 36 42.9 0.8 (0.6-1.2) Jess T et al, Gut 2006

Multivariate Analysis of Survival: Ulcerative Colitis Independent predictors of mortality Male gender Older age Diagnosis after 1980 was protective No association Extent (trend with extensive UC) Jess T et al, Gut 2006

Proctitis Classification by Extent Limited to rectum Within 15-20 cm of anal verge Left-sided colitis Distal to splenic flexure Within 60 cm of anal verge Extensive colitis Proximal to splenic flexure

UC Disease Extent Predicts Severity Setting Colectomy Rates Proctitis L-sided Extensive St Mark s 2% 6% 20% Cleveland Clinic 14% 52% 61% Copenhagen 9% 35% IBSEN 2% 2% 9% Lennard-Jones, Scand J Gastroenterol Suppl 1983 Farmer, Dig Dis Sci 1993 Langholz, Gastroenterol 1992 Moum,, Scand J Gastroenterol 1997

UC Disease Extent Influences Colorectal Cancer Risk Uppsala, Sweden: relative risk of CRC Proctitis, 1.7 Left-sided, 2.8 Extensive, 14.8 Cleveland Clinic: cumulative risk of CRC after 30 years of disease Left-sided, 4% Extensive, 25% Ekbom, N Engl J Med 1990 Mir-Madjlessi Madjlessi,, Cancer 1986

UC Disease Extent May Influence Mortality Copenhagen County Subgroup with extensive colitis had standardized mortality ratio (observed/expected) of 1.68 Other SMRs not significantly elevated Extended follow-up in this cohort Again showed elevated SMR in extensive Also showed a significantly lower SMR for proctitis Langholz,, Gastroenterology 1992 Winther,, Gastroenterology 2003

Is Age of Diagnosis a Prognosis Indicator? Some studies suggest that childhood-onset onset UC has higher rate of complications, is more severe, has higher risk of CRC, etc Data are conflicting Colectomy rates similar Likewise, older studies suggest that late- onset UC is milder Data again conflicting Insufficient evidence for age as a risk factor Devroede GJ et al, N Engl J Med 1971; Jackman RJ et al, Am J Dis Child 1940; Langholz E et al, Scand J Gastroenterol 1997; Brandt LJ et al, Am J Gastroenterol 1982.

IBD Associated with Primary Sclerosing Cholangitis ( PSC( PSC-IBD ) PSC and IBD are closely linked 5% of UC has PSC 70-80% of PSC has IBD (usually UC) PSC-IBD is typically extensive High rate of rectal sparing High rate of backwash ileitis PSC-IBD associated with dysplasia and CRC PSC-IBD more likely to develop pouchitis Is PSC-IBD a special phenotype of IBD? Peridigoto,, DDW abstract 1991; Penna,, Gut 1996; Faubion,, J Pediatr Gastroenterol Nutr 2001; Jayaram,, Gut 2001; Loftus, Gut 2005

Is Natural History of UC Different in Asia? Similar rates of relapse and proximal progression Perhaps a lower risk of CRC Lower prevalence of PSC Perhaps lower colectomy rates Less severe disease? Greater reluctance to accept surgery? Need more natural history cohorts with longer durations of follow-up Ling KL et al, J Clin Gastroenterol 2002; Park SH et al, Inflamm Bowel Dis 2007; Zheng JJ et al, J Dig Dis 2007.

Conclusions In our population-based inception cohort: Extensive disease, early steroids, early hospitalization were associated with subsequent hospitalization Male gender and diagnosis after 1980 were associated with increased risk of colectomy No risk factors for CRC were observed, although no CRC were observed in patients diagnosed after 1980

Conclusions (2) In our population-based cohort: Male gender and older age were risk factors for mortality but diagnosis after 1980 was protective A nonsignificant trend of increased mortality with increased extent was noted In other cohorts: Increased extent has been associated with increased colectomy rates, cancer risk and mortality Data on age at diagnosis conflicting PSC increases cancer risk and mortality

Conclusions (3) We need more natural history studies incorporating all of these endpoints as well as other markers Serologies? Genetic polymorphisms? Inflammatory biomarkers? CRP Fecal stool markers